Combination therapy with androgen deprivation for hormone sensitive prostate cancer: A new frontier
作者机构：Department of UrologyUniversity of Wisconsin-MadisonMadisonWIUSA Department of MedicineUniversity of Wisconsin-MadisonMadisonWIUSA University of Wisconsin-MadisonCarbone Cancer CenterUniversity of Wisconsin-MadisonMadisonWIUSA
出 版 物：《Asian Journal of Urology》 (亚洲泌尿外科杂志（英文）)
年 卷 期：2019年第6卷第1期
页 面：57-64页
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金：The study was supported by DOD Prostate Cancer Research Program PC150221 R.Stephenson Family Fund
主 题：Prostate cancer Cellular senescence Androgen deprivation therapy Combination therapy Synthetic lethal targeting Metformin Statins
摘 要：Androgen deprivation therapy(ADT)has been the standard of care for the last 75 years in metastatic hormone sensitive prostate cancer(PCa).However,this approach is rarely *** clinical trials have demonstrated that ADT combined with other agents,notably docetaxel and abiraterone,lead to improved *** mechanisms surrounding this improved cancer outcomes are incompletely *** response of cancer cells to ADT includes apoptosis and cell death,but a significant fraction remains *** laboratory has demonstrated both in vitro and in vivo that cellular senescence occurs in a subset of these *** senescence is a phenotype characterized by cell cycle arrest,senescenceassociated b-galactosidase(SA-b-gal),and a hypermetabolic *** features of cellular senescence include growth arrest and immune stimulation,although persistence may release cytokines and growth factors that are *** tumor cells generate a catabolic state with increased glycolysis,protein turnover and other metabolic changes that represent targets for drugs,like metformin,to be applied in a synthetic lethal *** review examines the response to ADT and the putative role of cellular senescence as a biomarker and therapeutic target in this context.
维普期刊数据库